These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status. Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299 [TBL] [Abstract][Full Text] [Related]
6. Advances in immunotherapy for MMR proficient colorectal cancer. Lote H; Starling N; Pihlak R; Gerlinger M Cancer Treat Rev; 2022 Dec; 111():102480. PubMed ID: 36335756 [TBL] [Abstract][Full Text] [Related]
7. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA). Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465 [TBL] [Abstract][Full Text] [Related]
8. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565 [TBL] [Abstract][Full Text] [Related]
9. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy. Yi B; Cheng H; Wyczechowska D; Yu Q; Li L; Ochoa AC; Riker AI; Xi Y Mol Cancer Ther; 2021 Jul; 20(7):1295-1304. PubMed ID: 33879557 [TBL] [Abstract][Full Text] [Related]
10. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4. van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734 [TBL] [Abstract][Full Text] [Related]
11. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study. Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P Front Immunol; 2022; 13():809971. PubMed ID: 35185898 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial. Gögenur M; Balsevicius L; Bulut M; Colak N; Justesen TF; Fiehn AK; Jensen MB; Høst-Rasmussen K; Cappelen B; Gaggar S; Tajik A; Zahid JA; Bennedsen ALB; D'Ondes TDB; Raskov H; Sækmose SG; Hansen LB; Salanti A; Brix S; Gögenur I J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37172969 [TBL] [Abstract][Full Text] [Related]
13. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692 [TBL] [Abstract][Full Text] [Related]
14. Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. Liu S; Gӧnen M; Stadler ZK; Weiser MR; Hechtman JF; Vakiani E; Wang T; Vyas M; Joneja U; Al-Bayati M; Segal NH; Smith JJ; King S; Guercio S; Ntiamoah P; Markowitz AJ; Zhang L; Cercek A; Garcia-Aguilar J; Saltz LB; Diaz LA; Klimstra DS; Shia J Mod Pathol; 2019 Jan; 32(1):110-121. PubMed ID: 30166615 [TBL] [Abstract][Full Text] [Related]
15. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Asaka S; Yen TT; Wang TL; Shih IM; Gaillard S Mod Pathol; 2019 Apr; 32(4):576-584. PubMed ID: 30401949 [TBL] [Abstract][Full Text] [Related]
16. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer. Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181 [TBL] [Abstract][Full Text] [Related]
17. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer. Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y; Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813 [TBL] [Abstract][Full Text] [Related]
18. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167 [TBL] [Abstract][Full Text] [Related]
19. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment. Zheng Z; Wieder T; Mauerer B; Schäfer L; Kesselring R; Braumüller H Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511431 [TBL] [Abstract][Full Text] [Related]
20. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]